Published online Jan 15, 2021. doi: 10.4251/wjgo.v13.i1.69
Peer-review started: November 10, 2020
First decision: November 30, 2020
Revised: December 6, 2020
Accepted: December 16, 2020
Article in press: December 16, 2020
Published online: January 15, 2021
Processing time: 58 Days and 1 Hours
The prognosis of patients with rectal cancer is poor and the mortality rate is high. The effectiveness and safety of intraoperative radiotherapy (IORT) for rectal cancer still controversial.
Previous studies have demonstrated that adding IORT to traditional treatment of rectal cancer not only reduces the local recurrence rate of advanced rectal cancer but also influences the local control rate of locally recurrent rectal cancer. However, a recent randomized controlled trial (RCT) showed that IORT cannot be recommended as a standard therapy to compensate less radical resection for advanced lower rectal cancer. It is necessary to perform a meta-analysis to systematically and comprehensively investigate the effectiveness and safety of IORT in the treatment of rectal cancer.
A systematic review and meta-analysis to evaluate the value of IORT for patients with rectal cancer.
We searched PubMed, Embase, Cochrane Library, Web of Science databases and conference abstracts and included RCTs and observational studies on IORT vs non-IORT for rectal cancer. Dichotomous variables were evaluated by odds ratio (OR) and 95% confidence interval (CI), hazard ratio (HR) and 95%CI was used as a summary statistic of survival outcomes. Statistical analyses were performed using Stata V.15.0 and Review Manager 5.3 software.
In this study, 3 RCTs and 12 observational studies were included with a total of 1460 patients, who were mainly residents of Europe, the United States, and Asia. Our results did not show significant differences in 5-year overall survival (HR = 0.80, 95%CI = 0.60-1.06; P = 0.126), 5-year disease-free survival (HR = 0.94, 95%CI = 0.73-1.22; P = 0.650); abscess: (OR = 1.10, 95%CI = 0.67-1.80; P = 0.713); fistulae (OR = 0.79, 95%CI = 0.33-1.89; P = 0.600); wound complication (OR = 1.21, 95%CI = 0.62-2.36; P = 0.575); anastomotic leakage (OR = 1.09, 95%CI = 0.59-2.02; P = 0.775); and neurogenic bladder dysfunction (OR = 0.69, 95%CI = 0.31-1.55; P = 0.369). However, the meta-analysis of 5-year local control was significantly different (OR = 3.07, 95%CI = 1.66-5.66; P = 0.000).
The advantage of IORT is mainly reflected in 5-year local control but it is not statistically significant for 5-year overall survival, 5-year disease-free survival, and complications.
Several limitations in this analysis should be carefully addressed. First, the randomization in the original research was limited. There were few controlled experiments and the sample size was irregular. Second, although most patients were treated in large tertiary cancer centers, the inclusion criteria for patients were different. Moreover, during treatment, the assessment methods of the outcome index was related to the proficiency of the surgeon. In addition, there were differences in the surgical procedures in this research, which may be a confounding factor for the results. Finally, our research is a secondary study and differences in the original data cannot be controlled for, including experimental design, inclusion criteria, and the original study included, which may affect the reliability of the results.